NCT06798194
Multimodal AI-based Region-specific Ablation Planning for Hepatocellular Carcinoma: Model Development, External Validation, and a Multicenter Randomized Trial
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Phase changed: Not specified → Not applicable Show 9 more changesShow less
- Eligibility criteria expanded, about 6 words
- Completed without a posted recruiting period
- Final enrollment: 232 participants (planned 300)
- Study completion date changed from estimate of Dec 30, 2027 to Nov 1, 2026
- Trial arms changed: 0 → 2
- Start date changed from estimate of Jan 30, 2025 to Jan 1, 2025
- Secondary endpoint revised
- Site contact updated
- Study title revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Local tumor progression
Timeframe: 1 years
Secondary (1)
complication and volume of ablation zone
Arms and interventions
HCA-PS groupExperimental
control groupNo intervention
Diagnostic tests: Post-ablation MRI is used to evaluate whether the ablation area of the tumor is consistent with the highly conformal ablation thermal field provided by the AI model.
Sites
1 site in 1 country
- Chinese PLA HospitalBeijing, China